Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) serves as a hub for tracking developments at the forefront of sustainable biotechnology. This resource aggregates official updates from the synthetic biology leader currently undergoing strategic restructuring while maintaining its commitment to transforming consumer markets through bioscience innovations.
Investors and industry observers will find comprehensive coverage of financial updates, leadership changes, and operational milestones. The collection includes press releases detailing AMRS's Chapter 11 restructuring progress, R&D advancements through its Lab-to-Market™ platform, and partnerships supporting its shift toward core biotechnology competencies.
Key content focuses on operational restructuring efforts, sustainability initiatives, and technology licensing agreements. Users can monitor updates about the company's consumer brand divestitures, cost optimization strategies, and ongoing supply chain relationships with global manufacturers.
Bookmark this page for streamlined access to verified AMRS communications, including regulatory filings and strategic partnership announcements. Check back regularly for the latest developments as Amyris positions itself for long-term stability in sustainable ingredient markets.
On February 28, 2023, Alisa Volkman and Naomi Watts announced The New Pause, a symposium focused on menopause, scheduled for March 11, 2023, in Santa Monica, California. Building on their successful NYC event, the symposium aims to destigmatize menopause and empower women with knowledge. Key topics include biology, relationships, and health during menopause, featuring experts like Dr. Avrum Bluming and Molly Ringwald. The event reflects a growing momentum in discussing menopause, highlighting the importance of dialogue and expert insights.
On February 22, 2023, Amyris (NASDAQ: AMRS) announced a strategic agreement with Givaudan, acquiring significant cosmetic ingredients such as Neossance® Squalane and Hemisqualane. This partnership aims to strengthen their leadership in biofermentation-based chemistry within the beauty industry as part of Givaudan's 2025 strategy. The deal includes an upfront cash payment, performance-based earnouts, and a manufacturing agreement. The acquisition is expected to add approximately USD 30 million in sales to Givaudan's results for 2022. Regulatory approvals are pending for the transaction.
Amyris, Inc. (Nasdaq: AMRS) has launched a new haircare line, 4U by Tia, in collaboration with actress Tia Mowry, now available exclusively at Walmart. This line features eight products designed for textured hair (2A to 4C) and incorporates Amyris' patented ingredient, Hemi15, which is 100% vegan and free from silicones, sulfates, and parabens. The collaboration marks Amyris' fifth consumer brand introduced in Walmart stores, aimed at providing affordable clean beauty options while promoting sustainability. However, the company faces risks including market volatility and supply chain disruptions that could impact operations.
Amyris, a synthetic biotechnology company (Nasdaq: AMRS), will present at the 41st Annual J.P. Morgan Health Care Conference on January 11, 2023, at 11:15 am PT in San Francisco. This event showcases Amyris's focus on sustainable consumption through its Lab-to-Market™ technology. A live webcast and replay will be accessible via the company's Investor Relations section. Amyris specializes in creating sustainable ingredients for health, beauty, and flavor markets, reaching over 300 million consumers globally.
Amyris, Inc. (Nasdaq: AMRS) has announced a registered direct offering of 20 million shares and warrants to purchase up to 15 million additional shares at a combined price of $1.50 per share. Concurrently, a private placement with Foris Ventures involves 13.33 million shares and warrants for 10 million shares, also priced at $1.50. The company expects gross proceeds of approximately $50 million to be used for general corporate purposes. The offerings are set for closing around December 30, 2022, subject to standard conditions.
Amyris, Inc. (Nasdaq: AMRS) has finalized key financial terms for a strategic transaction valued at over $500 million for exclusive rights to supply two ingredients. This transaction is pending antitrust review under the Hart-Scott-Rodino Act, with expectations to close in early Q1 2023. As part of the deal, Amyris will maintain the development and manufacturing of these ingredients, while also entering a long-term R&D collaboration. The company is optimistic about continued growth in its core business and the strategic value of this partnership.
Amyris, Inc. (Nasdaq: AMRS) reported an impressive 80% year-over-year growth in its direct-to-consumer sales during Cyber Monday on November 28, 2022. This growth is assessed based on a like-for-like comparison with the same period last year. CEO John Melo expressed satisfaction with the ongoing strong momentum across its consumer brands and overall business. The sales performance continues from a successful Black Friday week, indicating robust consumer interest in Amyris's sustainable products.
Amyris, a synthetic biotechnology company, announced record consumer sales for Black Friday week, from November 18 to November 26, 2022. The company experienced significant DTC sales growth, especially with its Biossance brand, which is projected to achieve $20 million in sales this month. Other brands like JVN and Rose Inc. reported over 400% DTC revenue growth compared to last year. CEO John Melo highlighted strong consumer demand for sustainable products and an effective omnichannel strategy, indicating a robust performance ahead.
Amyris, Inc. (AMRS) reported a strong Q3 2022, showcasing a core revenue of $71.1 million, up 49% year-over-year, fueled by record consumer revenue of $46.6 million—a 98% increase. The company successfully implemented its 'Fit to Win' initiatives, generating $10 million in earnings improvements. New funding of $180 million supports ongoing growth. Despite a GAAP net loss of $161.4 million and increased operating expenses, Amyris aims to maintain momentum heading into 2023, projecting core revenue to exceed $100 million in Q4.
Amyris, Inc. (Nasdaq: AMRS), a synthetic biotechnology company, will report its financial results for Q3 2022 on November 8, 2022, after market close. A conference call will follow at 1:30 PM PT, featuring CEO John Melo and CFO Han Kieftenbeld, discussing results and business updates. Amyris focuses on sustainable ingredients for Clean Health & Beauty and Flavors & Fragrances, leveraging its Lab-to-Market technology platform, which integrates machine learning and AI for rapid innovation, reaching over 300 million consumers through more than 20,000 products from top brands.
